News

Harbour BioMed files China IND for AI-designed obesity antibody LET003

What's the deal? Harbour BioMed, a Hong Kong-listed biopharmaceutical company, announced that China's drug regulator (the NMPA) has accepted its application to start clinical trials for LET003, its first drug candidate built with its Hu-mAtrIx artificial-intelligence antibody platform (18 November 2026). LET003 is a next-generation monoclonal antibody that blocks two receptors — ACVR2A and ACVR2B — which help regulate the balance between muscle and fat in the body, and it is being developed for overweight and obesity.

Why it matters: In animal studies, combining LET003 with semaglutide (the GLP-1 weight-loss medicine) significantly enhanced fat reduction while preserving lean muscle — a known shortcoming of current injectable weight-loss drugs — and at a lower dose it showed muscle-preserving effects comparable to bimagrumab, a benchmark muscle-building candidate. If that profile holds in humans, LET003 could become a best-in-class treatment that counters the muscle loss seen with existing obesity therapies.

Read more: BioSpace, 19 November 2026

More top stories